menu
    • menu
    [{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"Gene and Cell therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sana Biotechnology","amount2":0.69999999999999996,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Sana Biotechnology \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Glial progenitor cell therapy","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Sana Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Sana Biotechnology \/ Sana Biotechnology"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Fujifilm holding","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"iPSC-Derived Cell Therapies","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Sana Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Sana Biotechnology"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"IASO Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CT103A","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sana Biotechnology","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Sana Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Sana Biotechnology \/ Sana Biotechnology"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CD22-directed CAR T cell Therapy","moa":"CD22","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Sana Biotechnology \/ National Institutes of Health"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SC451","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SC451","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SG295","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SC291","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SC291","moa":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SC262","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0.13,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Morgan Stanley"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Morgan Stanley"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0.19,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Morgan Stanley"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"UP421","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sana Biotechnology \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Sana Biotechnology

    Menu

    Sana Biotechnology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC291,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sana Biotech Focuses on Type 1 Diabetes and Autoimmune Disease Clinical Studies

                            Details : SC291 is a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform for the treatment of B-cell mediated autoimmune diseases (AID).

                            Brand Name : SC291

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 04, 2024

                            Lead Product(s) : SC291,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC291

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Morgan Stanley

                            Deal Size : $189.7 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Sana Biotechnology Closes Upsized Public Offering and Underwriters' Option

                            Details : Proceeds will focus on developing SC291, an allogeneic CD19-directed CAR T cell therapy for relapsed/refractory B-cell malignancies, including Non-Hodgkin lymphoma & Chronic lymphocytic leukemia.

                            Brand Name : SC291

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 12, 2024

                            Lead Product(s) : SC291

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Morgan Stanley

                            Deal Size : $189.7 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC291

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Morgan Stanley

                            Deal Size : $165.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Sana Biotechnology Announces Pricing of Upsized Public Offering

                            Details : Proceeds will focus on developing SC291, an allogeneic CD19-directed CAR T cell therapy for relapsed/refractory B-cell malignancies, including Non-Hodgkin lymphoma & Chronic lymphocytic leukemia.

                            Brand Name : SC291

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 08, 2024

                            Lead Product(s) : SC291

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Morgan Stanley

                            Deal Size : $165.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC291

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Morgan Stanley

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Sana Biotechnology Announces Proposed Public Offering of Common Stock

                            Details : Proceeds will focus on developing SC291, an allogeneic CD19-directed CAR T cell therapy for relapsed/refractory B-cell malignancies, including Non-Hodgkin lymphoma & Chronic lymphocytic leukemia.

                            Brand Name : SC291

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 07, 2024

                            Lead Product(s) : SC291

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Morgan Stanley

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC262

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-mod...

                            Details : SC262 is a hypoimmune, CD22-directed allogeneic CAR T cell therapy derived from healthy donor CD4+ and CD8+ T cells. It is under preclinical development for the treatment of patients with relapsed or refractory B-cell malignancies.

                            Brand Name : SC262

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 05, 2023

                            Lead Product(s) : SC262

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UP421

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial...

                            Details : UP421 is an allogeneic, primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, which is being evaluated for the treatment of patients with type 1 diabetes.

                            Brand Name : UP421

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 17, 2023

                            Lead Product(s) : UP421

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC291

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-mod...

                            Details : SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis.

                            Brand Name : SC291

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 09, 2023

                            Lead Product(s) : SC291

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC291

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-mod...

                            Details : SC291 is a CD19-targeted allogeneic CAR T cell therapy developed using Sana’s hypoimmune platform. SC291 may result in longer CAR T cell persistence and a higher rate of durable complete responses for patients with B-cell lymphomas or leukemias.

                            Brand Name : SC291

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 26, 2023

                            Lead Product(s) : SC291

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SG295

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with S...

                            Details : The company expects to study SG295, an in vivo CAR T with CD8-targeted fusosome delivery of a CD19-targeted CAR, in B cell malignancies. With increased potency, SG295 has the potential to generate a comparable no. of CAR T cells to current ex vivo manufa...

                            Brand Name : SG295

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 11, 2022

                            Lead Product(s) : SG295

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Sana Biotechnology

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC291

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology...

                            Details : The SC291 preclinical data demonstrate these hypoimmunogenic CAR T cells are able to evade both the innate and adaptive arms of the immune system while retaining their antitumor activity.

                            Brand Name : SC291

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 03, 2022

                            Lead Product(s) : SC291

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth